L'Oréal ties part of its skincare sales momentum to the GLP-1 drug boom
L'Oréal, the world's largest cosmetics company, says the boom in GLP-1 weight-loss drugs, known by brands such as Ozempic, Wegovy or Mounjaro, is boosting beauty and skincare sales. CEO Nicolas Hieronimus said on an investor call that GLP-1 use is "a very important phenomenon" for the company. L'Oréal reported a 7.7% rise in third-quarter sales, above analysts' expectations.
In 30 seconds
- L'Oréal says GLP-1 use is affecting beauty consumption, particularly skincare.
- Its third-quarter sales rose 7.7% and beat analysts' expectations.
- Brands such as SkinCeuticals and Kiehl's have products aimed at countering skin sagging linked to rapid weight loss.
IASummary generated by artificial intelligence from a story by BBC. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.